Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2022 | Phase I study of CART-ddBCMA in R/R multiple myeloma

Matthew Frigault • 3 Jun 2022
ASCO 2022
Multiple Myeloma CAR-T CART-ddBCMA

Matthew J. Frigault, MD, Harvard Medical School, Boston, MA, discusses the safety and efficacy results of a Phase I study of CART-ddBCMA, an autologous anti-BCMA CAR-T cell therapy that utilizes a novel, synthetic binding domain, called a D-Domain, instead of a typical scFv binder, in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Matthew Frigault

Follow-up from a Phase I study of CART-ddBCMA for the treatment of R/R multiple myeloma 0:53
Follow-up from a Phase I study of CART-ddBCMA for the treatment of R/R multiple myeloma
Matthew Frigault • 10 Dec 2023
Itacitinib for the prevention of immune effector cell therapy–associated CRS 0:58
Itacitinib for the prevention of immune effector cell therapy–associated CRS
Matthew Frigault • 12 Dec 2023
Prophylaxis and management of CRS & ICANS
Bianca Santomasso et al. • 12 May 2023
Rapid CAR manufacture
Caron Jacobson et al. • 12 May 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals